The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 Duravelo-1 study: Preliminary results of nectin-4–targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer.
 
Patrizia Giannatempo
Research Funding - AstraZeneca (Inst)
 
Matthew Galsky
Consulting or Advisory Role - Abbvie; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Curis; Daiichi Sankyo Europe GmbH; EMD Serono; Gilead Sciences; Janssen; Merck; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Ignacio Duran
Honoraria - Astellas Pharma; AstraZeneca Spain; Bayer/Onyx; Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD Oncology; Roche/Genentech
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Immunomedics; Janssen Oncology; MSD Oncology; Novartis; Pfizer/EMD Serono; Pharmacyclics; Roche/Genentech; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca Spain (Inst); Bayer; Janssen Oncology (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca Spain; Bayer/Onyx; Gilead Sciences; Ipsen; Pfizer/EMD Serono; Roche/Genentech
 
Valentina Boni
Leadership - Director of Clinical Cancer Research, NEXT Madrid, Universitary Hospital QuirónSalud Pozuelo; IDMC Nanobiotix NANORAY-312/Novartis; Steering Committee CytomX Therapeutics
Stock and Other Ownership Interests - 1TRIALSP
Consulting or Advisory Role - Affirmed; Alentis Therapeutics; CytomX Therapeutics; EMD Serono; Guidepoint Pharmacy; Ideaya Biosciences; Janssen; Lilly; Loxo Therapeutics; OncoArt; Puma Biotechnology
Research Funding - Abbvie (Inst); ACEO (Inst); Adaptaimmune (Inst); Affimed NV (Inst); Amcure (Inst); AMGEN (Inst); Amunix (Inst); Astellas Pharma (Inst); AstraZeneca Canada (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Boheringer Ingelheilm (Inst); Boston Therapeutics (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); Constellation Pharmaceutical (Inst); Crescendo Biologics (Inst); Cullinan Oncology (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Dynavax Technologies (Inst); Ellipses Pharma (Inst); Exelesis (Inst); Famawav (Inst); Genentech/Roche (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Ideaya Bioscience (Inst); Incyte (Inst); Invox Pharma (Inst); iOMX Therapeutics (Inst); Ipsen (Inst); Janssen (Inst); Kronos Bio (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); Menarini (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Moderna Therapeutics (Inst); MSD (Inst); Nanobiotix (Inst); Navire (Inst); Nektar (Inst); Nektar (Inst); Novartis (Inst); Orca (Inst); Pfizer (Inst); PharmaMar (Inst); Principa Biopharma (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Ribbon (Inst); Ryvu Therapeutics (Inst); Salubris Biotherapeutics (Inst); Sanofi (Inst); Scorpion Therapeutics (Inst); Seagen (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); Stemline Therapeutics (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Tolrelmo Therapeutics (Inst); Totus Medicine (Inst); Transgene (Inst); Tyra Bioscience (Inst); UroGen pharma (Inst); Vividion Therapeutics (Inst); Xencor (Inst); Zai Biopharmaceutical (Inst); Zenith (Inst)
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Consulting or Advisory Role - AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Catalym; Genenta Science; Gilead Sciences; Incyte; Johnson & Johnson/Janssen; Merck Serono; Merck Sharp & Dohme; Peerview; PeerVoice; Samsung Bioepis; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Gilead Sciences (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Janssen; Merck Sharp & Dohme
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS
 
Meredith McKean
Consulting or Advisory Role - Castle Biosciences (Inst); IQVIA (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
Research Funding - AADi (Inst); Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); ASCO (Inst); Astellas Pharma (Inst); Aulos Bioscience (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); NucMito Pharmaceuticals (Inst); OncoC4 (Inst); Oncorus (Inst); OnKure (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Poseida (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)
 
Loic Verlingue
Leadership - Resolved
Consulting or Advisory Role - Adaptherapy
Research Funding - Bristol-Myers Squibb
 
Rama Balaraman
Leadership - Head of Research
Honoraria - AstraZeneca; Celgene; Genentech; GlaxoSmithKline
Consulting or Advisory Role - Alphasights; AstraZeneca
Research Funding - Bicara Therapeutics
Travel, Accommodations, Expenses - AstraZeneca
 
Leslie DeMars
Employment - Bicycle Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics
Travel, Accommodations, Expenses - Bicycle Therapeutics; Mersana
 
Kate Josephs
Employment - Bicycle Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics
 
Cong Xu
Employment - Bicycle Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics
 
Oscar Reig Torras
Stock and Other Ownership Interests - Bristol Myers Squibb; Merck; Pfizer
Honoraria - Astellas Pharma; BMS; Ipsen; Merck; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Pfizer; Sanofi
Travel, Accommodations, Expenses - Ipsen; Merck